Share Price and Basic Stock Data
Last Updated: January 14, 2026, 1:34 pm
| PEG Ratio | 11.66 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Par Drugs & Chemicals Ltd operates in the pharmaceuticals sector, reporting a market capitalization of ₹122 Cr and a share price of ₹99.1. The company has displayed a steady revenue growth trajectory, with total sales rising from ₹55.85 Cr in FY 2020 to ₹95.75 Cr in FY 2023. In the trailing twelve months (TTM), sales stood at ₹98.42 Cr, indicating a robust operational performance. Quarterly sales show fluctuations, with the most recent quarter ending September 2023 recording ₹25.89 Cr, up from ₹22.93 Cr in the previous quarter. The company’s performance over the last fiscal years has been characterized by a consistent increase in sales, although there were slight declines in certain quarters, notably in December 2023 and March 2024. This reflects the inherent volatility in the pharmaceutical market, which can be influenced by various external factors, including regulatory changes and market demand.
Profitability and Efficiency Metrics
Par Drugs & Chemicals has demonstrated commendable profitability metrics, with a reported net profit of ₹9.69 Cr and a profit margin of 13.22% for FY 2025. The operating profit margin (OPM) recorded an average of 21.14% in the most recent quarter, showcasing efficient cost management despite fluctuations in quarterly performance. The company reported a return on equity (ROE) of 13.6% and a return on capital employed (ROCE) of 18.4%, indicating effective utilization of shareholders’ funds and overall capital. The interest coverage ratio is particularly strong at 263.72x, reflecting the absence of debt and the company’s capacity to meet interest obligations comfortably. However, the OPM has displayed variability, with a high of 32.92% in September 2024, indicating potential concerns regarding cost control during periods of lower sales.
Balance Sheet Strength and Financial Ratios
The balance sheet of Par Drugs & Chemicals is robust, with zero borrowings reported, which is a significant strength, especially in a capital-intensive industry. Reserves have steadily increased from ₹34.46 Cr in FY 2020 to ₹94.13 Cr in FY 2025, reflecting the company’s commitment to retaining earnings for future growth. The current ratio stands at 3.31, indicating healthy short-term liquidity, while the quick ratio is at 2.94, showcasing the company’s ability to meet its short-term obligations without relying on inventory sales. The price-to-book value (P/BV) ratio is relatively modest at 1.06x, suggesting the stock is trading close to its book value, which can be appealing for value investors. Furthermore, the asset turnover ratio of 0.91 indicates efficient use of assets to generate revenue, although it is slightly below the sector average, which may warrant further analysis.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Par Drugs & Chemicals reveals a significant promoter holding of 73.37%, indicating strong management control. Notably, the company has not attracted foreign institutional investors (FIIs) or domestic institutional investors (DIIs), with FIIs holding only 0.00% as of the latest reports. Public shareholding stands at 26.63%, which includes a growing number of shareholders, increasing from 5,676 in December 2022 to 14,280 in September 2025. This growth in the number of shareholders may reflect increasing investor interest and confidence in the company’s future prospects. However, the absence of institutional backing could raise concerns about the stock’s liquidity and stability in volatile market conditions. The lack of dividend payouts over the years indicates a focus on reinvestment for growth rather than immediate returns to shareholders, which may appeal to long-term investors.
Outlook, Risks, and Final Insight
Looking ahead, Par Drugs & Chemicals is well-positioned for growth, bolstered by a strong balance sheet and healthy profitability metrics. However, the company faces risks, including potential fluctuations in sales and operating profits, as evidenced by quarterly variances. The pharmaceutical industry is also subject to strict regulatory scrutiny, which could impact operations. Moreover, the lack of debt provides a cushion against economic downturns but could limit expansion opportunities if the company does not leverage its strong position. In scenarios where operational efficiencies improve and sales stabilize, the company could see enhanced profitability and shareholder returns. Conversely, if market conditions worsen or operational challenges persist, the company may struggle to maintain its current performance levels. Overall, while Par Drugs & Chemicals exhibits several strengths, it must navigate inherent industry risks to sustain its growth trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,065 Cr. | 373 | 479/192 | 84.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.6 Cr. | 40.0 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,190.43 Cr | 1,122.41 | 52.64 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.82 | 22.93 | 24.49 | 22.93 | 25.89 | 24.00 | 22.82 | 22.61 | 34.66 | 21.38 | 22.33 | 26.05 | 28.66 |
| Expenses | 18.92 | 19.70 | 19.10 | 18.79 | 18.53 | 18.77 | 16.72 | 18.37 | 23.25 | 19.95 | 19.90 | 22.49 | 22.60 |
| Operating Profit | 5.90 | 3.23 | 5.39 | 4.14 | 7.36 | 5.23 | 6.10 | 4.24 | 11.41 | 1.43 | 2.43 | 3.56 | 6.06 |
| OPM % | 23.77% | 14.09% | 22.01% | 18.05% | 28.43% | 21.79% | 26.73% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% | 21.14% |
| Other Income | 0.02 | 0.04 | 0.03 | 0.01 | 0.05 | 0.23 | -0.05 | 0.07 | 1.02 | 0.27 | 0.79 | 1.84 | 0.48 |
| Interest | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.02 | 0.05 | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | 0.05 |
| Depreciation | 0.91 | 0.74 | 0.85 | 0.83 | 0.85 | 0.87 | 0.89 | 0.90 | 0.91 | 0.91 | 0.92 | 0.90 | 0.94 |
| Profit before tax | 4.98 | 2.50 | 4.54 | 3.30 | 6.53 | 4.57 | 5.11 | 3.39 | 11.49 | 0.78 | 2.28 | 4.48 | 5.55 |
| Tax % | 25.10% | 25.20% | 24.01% | 25.15% | 25.27% | 25.16% | 27.20% | 25.07% | 25.15% | 24.36% | 27.63% | 25.67% | 25.59% |
| Net Profit | 3.73 | 1.87 | 3.45 | 2.47 | 4.89 | 3.42 | 3.72 | 2.53 | 8.60 | 0.58 | 1.65 | 3.33 | 4.13 |
| EPS in Rs | 3.03 | 1.52 | 2.80 | 2.01 | 3.97 | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.71 | 3.36 |
Last Updated: December 29, 2025, 4:36 pm
Below is a detailed analysis of the quarterly data for Par Drugs & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 28.66 Cr.. The value appears strong and on an upward trend. It has increased from 26.05 Cr. (Jun 2025) to 28.66 Cr., marking an increase of 2.61 Cr..
- For Expenses, as of Sep 2025, the value is 22.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 22.49 Cr. (Jun 2025) to 22.60 Cr., marking an increase of 0.11 Cr..
- For Operating Profit, as of Sep 2025, the value is 6.06 Cr.. The value appears strong and on an upward trend. It has increased from 3.56 Cr. (Jun 2025) to 6.06 Cr., marking an increase of 2.50 Cr..
- For OPM %, as of Sep 2025, the value is 21.14%. The value appears strong and on an upward trend. It has increased from 13.67% (Jun 2025) to 21.14%, marking an increase of 7.47%.
- For Other Income, as of Sep 2025, the value is 0.48 Cr.. The value appears to be declining and may need further review. It has decreased from 1.84 Cr. (Jun 2025) to 0.48 Cr., marking a decrease of 1.36 Cr..
- For Interest, as of Sep 2025, the value is 0.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Jun 2025) to 0.05 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Sep 2025, the value is 0.94 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.90 Cr. (Jun 2025) to 0.94 Cr., marking an increase of 0.04 Cr..
- For Profit before tax, as of Sep 2025, the value is 5.55 Cr.. The value appears strong and on an upward trend. It has increased from 4.48 Cr. (Jun 2025) to 5.55 Cr., marking an increase of 1.07 Cr..
- For Tax %, as of Sep 2025, the value is 25.59%. The value appears to be improving (decreasing) as expected. It has decreased from 25.67% (Jun 2025) to 25.59%, marking a decrease of 0.08%.
- For Net Profit, as of Sep 2025, the value is 4.13 Cr.. The value appears strong and on an upward trend. It has increased from 3.33 Cr. (Jun 2025) to 4.13 Cr., marking an increase of 0.80 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.36. The value appears strong and on an upward trend. It has increased from 2.71 (Jun 2025) to 3.36, marking an increase of 0.65.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:51 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.27 | 33.25 | 33.26 | 48.77 | 42.38 | 46.33 | 55.85 | 60.75 | 75.07 | 95.75 | 95.64 | 100.97 | 98.42 |
| Expenses | 20.01 | 25.88 | 26.07 | 40.31 | 34.40 | 38.13 | 46.41 | 44.74 | 58.82 | 77.55 | 72.82 | 81.47 | 84.94 |
| Operating Profit | 7.26 | 7.37 | 7.19 | 8.46 | 7.98 | 8.20 | 9.44 | 16.01 | 16.25 | 18.20 | 22.82 | 19.50 | 13.48 |
| OPM % | 26.62% | 22.17% | 21.62% | 17.35% | 18.83% | 17.70% | 16.90% | 26.35% | 21.65% | 19.01% | 23.86% | 19.31% | 13.70% |
| Other Income | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.09 | 0.10 | 2.18 | 0.18 | 0.24 | 0.24 | 2.15 | 3.38 |
| Interest | 3.91 | 3.86 | 3.57 | 2.50 | 2.33 | 1.96 | 0.79 | 0.64 | 0.45 | 0.13 | 0.11 | 0.08 | 0.10 |
| Depreciation | 2.17 | 2.33 | 2.65 | 2.82 | 3.14 | 3.04 | 2.76 | 2.82 | 3.28 | 3.23 | 3.44 | 3.65 | 3.67 |
| Profit before tax | 1.21 | 1.22 | 1.01 | 3.18 | 2.55 | 3.29 | 5.99 | 14.73 | 12.70 | 15.08 | 19.51 | 17.92 | 13.09 |
| Tax % | 39.67% | 27.05% | 58.42% | 42.14% | 41.57% | 23.71% | 20.53% | 21.11% | 27.48% | 24.87% | 25.73% | 25.50% | |
| Net Profit | 0.72 | 0.89 | 0.42 | 1.85 | 1.50 | 2.51 | 4.76 | 11.61 | 9.21 | 11.33 | 14.50 | 13.36 | 9.69 |
| EPS in Rs | 1.33 | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 10.86 | 7.88 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 32.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 23.61% | -52.81% | 340.48% | -18.92% | 67.33% | 89.64% | 143.91% | -20.67% | 23.02% | 27.98% | -7.86% |
| Change in YoY Net Profit Growth (%) | 0.00% | -76.42% | 393.29% | -359.40% | 86.25% | 22.31% | 54.27% | -164.58% | 43.69% | 4.96% | -35.84% |
Par Drugs & Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 10% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 23% |
| 3 Years: | 13% |
| TTM: | -3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | -17% |
| 1 Year: | -58% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 14% |
Last Updated: September 5, 2025, 12:05 pm
Balance Sheet
Last Updated: December 4, 2025, 1:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.70 | 2.70 | 2.70 | 2.70 | 2.70 | 4.48 | 6.15 | 6.15 | 12.30 | 12.30 | 12.30 | 12.30 | 12.30 |
| Reserves | 7.71 | 8.58 | 8.91 | 10.75 | 12.25 | 24.55 | 34.46 | 46.06 | 47.57 | 58.93 | 73.33 | 86.67 | 94.13 |
| Borrowings | 44.12 | 38.46 | 36.49 | 30.55 | 28.87 | 11.58 | 6.01 | 8.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 6.86 | 8.85 | 9.93 | 12.05 | 10.12 | 10.66 | 13.49 | 15.86 | 18.82 | 17.64 | 15.98 | 20.42 | 21.09 |
| Total Liabilities | 61.39 | 58.59 | 58.03 | 56.05 | 53.94 | 51.27 | 60.11 | 76.39 | 78.69 | 88.87 | 101.61 | 119.39 | 127.52 |
| Fixed Assets | 47.06 | 45.11 | 42.61 | 41.53 | 39.04 | 36.34 | 34.40 | 29.91 | 34.10 | 38.45 | 41.31 | 38.91 | 37.70 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | 4.52 | 0.25 | 0.25 | 0.03 | 0.00 | 0.07 |
| Investments | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 25.07 | 26.72 |
| Other Assets | 14.33 | 13.48 | 15.36 | 14.46 | 14.84 | 14.87 | 24.91 | 41.95 | 44.33 | 50.16 | 60.26 | 55.41 | 63.03 |
| Total Assets | 61.39 | 58.59 | 58.03 | 56.05 | 53.94 | 51.27 | 60.11 | 76.39 | 78.69 | 88.87 | 101.61 | 119.39 | 127.52 |
Below is a detailed analysis of the balance sheet data for Par Drugs & Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 12.30 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.30 Cr..
- For Reserves, as of Sep 2025, the value is 94.13 Cr.. The value appears strong and on an upward trend. It has increased from 86.67 Cr. (Mar 2025) to 94.13 Cr., marking an increase of 7.46 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 21.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.42 Cr. (Mar 2025) to 21.09 Cr., marking an increase of 0.67 Cr..
- For Total Liabilities, as of Sep 2025, the value is 127.52 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 119.39 Cr. (Mar 2025) to 127.52 Cr., marking an increase of 8.13 Cr..
- For Fixed Assets, as of Sep 2025, the value is 37.70 Cr.. The value appears to be declining and may need further review. It has decreased from 38.91 Cr. (Mar 2025) to 37.70 Cr., marking a decrease of 1.21 Cr..
- For CWIP, as of Sep 2025, the value is 0.07 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.07 Cr., marking an increase of 0.07 Cr..
- For Investments, as of Sep 2025, the value is 26.72 Cr.. The value appears strong and on an upward trend. It has increased from 25.07 Cr. (Mar 2025) to 26.72 Cr., marking an increase of 1.65 Cr..
- For Other Assets, as of Sep 2025, the value is 63.03 Cr.. The value appears strong and on an upward trend. It has increased from 55.41 Cr. (Mar 2025) to 63.03 Cr., marking an increase of 7.62 Cr..
- For Total Assets, as of Sep 2025, the value is 127.52 Cr.. The value appears strong and on an upward trend. It has increased from 119.39 Cr. (Mar 2025) to 127.52 Cr., marking an increase of 8.13 Cr..
Notably, the Reserves (94.13 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -36.86 | -31.09 | -29.30 | -22.09 | -20.89 | -3.38 | 3.43 | 7.69 | 16.25 | 18.20 | 22.82 | 19.50 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 104 | 83 | 81 | 61 | 75 | 67 | 81 | 75 | 90 | 65 | 52 | 60 |
| Inventory Days | 129 | 111 | 158 | 69 | 83 | 81 | 45 | 50 | 60 | 49 | 45 | 58 |
| Days Payable | 171 | 184 | 183 | 135 | 107 | 94 | 96 | 112 | 135 | 73 | 58 | 104 |
| Cash Conversion Cycle | 62 | 10 | 57 | -5 | 51 | 55 | 30 | 13 | 14 | 40 | 40 | 15 |
| Working Capital Days | 102 | 61 | 66 | -46 | -26 | 13 | 39 | 24 | 61 | 50 | 40 | 39 |
| ROCE % | 10% | 9% | 12% | 11% | 12% | 16% | 25% | 22% | 23% | 25% | 18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 10.86 | 11.78 | 9.21 | 7.49 | 18.87 |
| Diluted EPS (Rs.) | 10.86 | 11.78 | 9.21 | 7.49 | 18.87 |
| Cash EPS (Rs.) | 13.82 | 14.58 | 11.84 | 10.15 | 23.45 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 80.44 | 69.59 | 57.90 | 48.66 | 84.87 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 80.44 | 69.59 | 57.90 | 48.66 | 84.87 |
| Dividend / Share (Rs.) | 0.00 | 0.00 | 0.00 | 1.25 | 0.00 |
| Revenue From Operations / Share (Rs.) | 82.06 | 77.73 | 77.81 | 61.01 | 98.75 |
| PBDIT / Share (Rs.) | 17.60 | 18.74 | 14.99 | 13.36 | 26.34 |
| PBIT / Share (Rs.) | 14.63 | 15.95 | 12.36 | 10.69 | 21.75 |
| PBT / Share (Rs.) | 14.57 | 15.86 | 12.25 | 10.32 | 20.71 |
| Net Profit / Share (Rs.) | 10.86 | 11.79 | 9.21 | 7.49 | 18.87 |
| PBDIT Margin (%) | 21.44 | 24.11 | 19.26 | 21.89 | 26.66 |
| PBIT Margin (%) | 17.83 | 20.51 | 15.88 | 17.52 | 22.02 |
| PBT Margin (%) | 17.75 | 20.40 | 15.74 | 16.92 | 20.97 |
| Net Profit Margin (%) | 13.22 | 15.16 | 11.83 | 12.27 | 19.11 |
| Return on Networth / Equity (%) | 13.49 | 16.93 | 15.91 | 15.38 | 22.23 |
| Return on Capital Employeed (%) | 17.51 | 22.00 | 20.31 | 20.61 | 22.15 |
| Return On Assets (%) | 11.18 | 14.27 | 12.75 | 11.70 | 15.20 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 |
| Asset Turnover Ratio (%) | 0.91 | 1.00 | 1.14 | 0.96 | 0.89 |
| Current Ratio (X) | 3.31 | 4.79 | 3.53 | 2.93 | 2.58 |
| Quick Ratio (X) | 2.94 | 4.46 | 3.15 | 2.61 | 2.39 |
| Inventory Turnover Ratio (X) | 19.64 | 6.97 | 8.13 | 7.68 | 7.47 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 16.69 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 12.31 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 83.31 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 87.69 | 0.00 |
| Interest Coverage Ratio (X) | 263.72 | 215.31 | 138.48 | 36.19 | 25.22 |
| Interest Coverage Ratio (Post Tax) (X) | 163.70 | 136.40 | 86.09 | 21.28 | 15.99 |
| Enterprise Value (Cr.) | 76.93 | 228.45 | 150.02 | 180.36 | 62.64 |
| EV / Net Operating Revenue (X) | 0.76 | 2.39 | 1.57 | 2.40 | 1.03 |
| EV / EBITDA (X) | 3.55 | 9.91 | 8.13 | 10.97 | 3.87 |
| MarketCap / Net Operating Revenue (X) | 1.03 | 2.77 | 1.80 | 2.62 | 1.25 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 83.30 | 0.00 |
| Price / BV (X) | 1.06 | 3.10 | 2.42 | 3.28 | 1.46 |
| Price / Net Operating Revenue (X) | 1.03 | 2.77 | 1.80 | 2.62 | 1.25 |
| EarningsYield | 0.12 | 0.05 | 0.06 | 0.04 | 0.15 |
After reviewing the key financial ratios for Par Drugs & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
- For Diluted EPS (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.78 (Mar 24) to 10.86, marking a decrease of 0.92.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.82. This value is within the healthy range. It has decreased from 14.58 (Mar 24) to 13.82, marking a decrease of 0.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 80.44. It has increased from 69.59 (Mar 24) to 80.44, marking an increase of 10.85.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.06. It has increased from 77.73 (Mar 24) to 82.06, marking an increase of 4.33.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.60. This value is within the healthy range. It has decreased from 18.74 (Mar 24) to 17.60, marking a decrease of 1.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 15.95 (Mar 24) to 14.63, marking a decrease of 1.32.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.57. This value is within the healthy range. It has decreased from 15.86 (Mar 24) to 14.57, marking a decrease of 1.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 10.86. This value is within the healthy range. It has decreased from 11.79 (Mar 24) to 10.86, marking a decrease of 0.93.
- For PBDIT Margin (%), as of Mar 25, the value is 21.44. This value is within the healthy range. It has decreased from 24.11 (Mar 24) to 21.44, marking a decrease of 2.67.
- For PBIT Margin (%), as of Mar 25, the value is 17.83. This value is within the healthy range. It has decreased from 20.51 (Mar 24) to 17.83, marking a decrease of 2.68.
- For PBT Margin (%), as of Mar 25, the value is 17.75. This value is within the healthy range. It has decreased from 20.40 (Mar 24) to 17.75, marking a decrease of 2.65.
- For Net Profit Margin (%), as of Mar 25, the value is 13.22. This value exceeds the healthy maximum of 10. It has decreased from 15.16 (Mar 24) to 13.22, marking a decrease of 1.94.
- For Return on Networth / Equity (%), as of Mar 25, the value is 13.49. This value is below the healthy minimum of 15. It has decreased from 16.93 (Mar 24) to 13.49, marking a decrease of 3.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.51. This value is within the healthy range. It has decreased from 22.00 (Mar 24) to 17.51, marking a decrease of 4.49.
- For Return On Assets (%), as of Mar 25, the value is 11.18. This value is within the healthy range. It has decreased from 14.27 (Mar 24) to 11.18, marking a decrease of 3.09.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.91. It has decreased from 1.00 (Mar 24) to 0.91, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.79 (Mar 24) to 3.31, marking a decrease of 1.48.
- For Quick Ratio (X), as of Mar 25, the value is 2.94. This value exceeds the healthy maximum of 2. It has decreased from 4.46 (Mar 24) to 2.94, marking a decrease of 1.52.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 19.64. This value exceeds the healthy maximum of 8. It has increased from 6.97 (Mar 24) to 19.64, marking an increase of 12.67.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 263.72. This value is within the healthy range. It has increased from 215.31 (Mar 24) to 263.72, marking an increase of 48.41.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.70. This value is within the healthy range. It has increased from 136.40 (Mar 24) to 163.70, marking an increase of 27.30.
- For Enterprise Value (Cr.), as of Mar 25, the value is 76.93. It has decreased from 228.45 (Mar 24) to 76.93, marking a decrease of 151.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.76. This value is below the healthy minimum of 1. It has decreased from 2.39 (Mar 24) to 0.76, marking a decrease of 1.63.
- For EV / EBITDA (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 5. It has decreased from 9.91 (Mar 24) to 3.55, marking a decrease of 6.36.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 3.10 (Mar 24) to 1.06, marking a decrease of 2.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has decreased from 2.77 (Mar 24) to 1.03, marking a decrease of 1.74.
- For EarningsYield, as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.05 (Mar 24) to 0.12, marking an increase of 0.07.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Par Drugs & Chemicals Ltd:
- Net Profit Margin: 13.22%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.51% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 13.49% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 163.7
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 11.9 (Industry average Stock P/E: 52.64)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 13.22%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 815, Nilamber Triumph, Vadodra Gujarat 390007 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Falgun Vallabhbhai Savani | Chairman & Managing Director |
| Mr. Jignesh Vallabhbhai Savani | Executive Director & CEO |
| Mr. Pravin Manjibhai Bhayani | Independent Director |
| Mrs. Kajal Chintanbhai Vaghani | Independent Director |
| Mrs. Krishna Mitulbhai Shah | Independent Director |
| Mrs. Bintal Bhaveshkumar Shah | Independent Director |
FAQ
What is the intrinsic value of Par Drugs & Chemicals Ltd?
Par Drugs & Chemicals Ltd's intrinsic value (as of 14 January 2026) is ₹114.23 which is 22.04% higher the current market price of ₹93.60, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹115 Cr. market cap, FY2025-2026 high/low of ₹206/81.0, reserves of ₹94.13 Cr, and liabilities of ₹127.52 Cr.
What is the Market Cap of Par Drugs & Chemicals Ltd?
The Market Cap of Par Drugs & Chemicals Ltd is 115 Cr..
What is the current Stock Price of Par Drugs & Chemicals Ltd as on 14 January 2026?
The current stock price of Par Drugs & Chemicals Ltd as on 14 January 2026 is ₹93.6.
What is the High / Low of Par Drugs & Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Par Drugs & Chemicals Ltd stocks is ₹206/81.0.
What is the Stock P/E of Par Drugs & Chemicals Ltd?
The Stock P/E of Par Drugs & Chemicals Ltd is 11.9.
What is the Book Value of Par Drugs & Chemicals Ltd?
The Book Value of Par Drugs & Chemicals Ltd is 86.5.
What is the Dividend Yield of Par Drugs & Chemicals Ltd?
The Dividend Yield of Par Drugs & Chemicals Ltd is 0.00 %.
What is the ROCE of Par Drugs & Chemicals Ltd?
The ROCE of Par Drugs & Chemicals Ltd is 18.4 %.
What is the ROE of Par Drugs & Chemicals Ltd?
The ROE of Par Drugs & Chemicals Ltd is 13.6 %.
What is the Face Value of Par Drugs & Chemicals Ltd?
The Face Value of Par Drugs & Chemicals Ltd is 10.0.